Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company (NYSE:LLY) even as it fell into a bear market after peaking in August.

Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose ...

Eli Lilly LLY-2.01%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Drug company calls on insurers and federal programs to include coverage of obesity as a chronic disease Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound ...

Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

Eli LIlly & Co. said Tuesday it is launching 7.5 and 10 milligram versions of its Zepbound single-dose vials at a price of $499-a-month for self-pay patients, down from $699 previously.